• 84.1k views

HRD Evaluation in 4 types of Cancers

HRD (Homologous Recombination Deficiency) evaluation plays a crucial role in assessing the genetic characteristics and treatment strategies for various types of cancers. In breast cancer, it helps identify patients with DNA repair defects that may benefit from targeted therapies. In ovarian cancer aids in determining the potential responsiveness to PARP inhibitors, a class of drugs used in DNA repair-deficient tumors. In prostate cancer, it assists in identifying patients who may respond well to certain DNA-damaging agents or PARP inhibitors. Understanding HRD status in pancreatic cancer helps in identifying patients with defects in DNA repair pathways, which may influence treatment decisions. In lung cancer allows for the identification of patients who may benefit from DNA damage response-targeted therapies.

About the Speaker

Dr. Shibichakravarthy Kannan
 
  Profile Image

Dr. Shibichakravarthy Kannan

Precision Oncology, Founder & CEO in Oncophenomics Inc., Hyderabad

Upcoming Case Discussions

Leave a Comment

Your email address will not be published.

Author Post

authorimage

Impact

+

Talks

+

webinar

+

no.of registrations

One liner about speaker

Why is speaker relevant?

Dr. Shibichakravarthy Kannan 's Talks on Assimilate

webinar
Dr. Shibichakravarthy Kannan
  • 18th-July-2023, TIME : 5:00PM - 6:00PM
  • 0

HRD (Homologous Recombination Deficiency) evaluation plays a crucial role in assessing the genetic characteristics and treatment strategies for various types of cancers. In breast cancer, it helps identify patients with DNA repair defects that may benefit from targeted therapies. In ovarian cancer aids in determining the potential responsiveness to PARP inhibitors, a class of drugs used in DNA repair-deficient tumors. In prostate cancer, it assists in identifying patients who may respond well to certain DNA-damaging agents or PARP inhibitors. Understanding HRD status in pancreatic cancer helps in identifying patients with defects in DNA repair pathways, which may influence treatment decisions. In lung cancer allows for the identification of patients who may benefit from DNA damage response-targeted therapies.

webinar
Dr. Shibichakravarthy Kannan
  • 18th-July-2023, TIME : 5:00PM - 6:00PM
  • 0

HRD (Homologous Recombination Deficiency) evaluation plays a crucial role in assessing the genetic characteristics and treatment strategies for various types of cancers. In breast cancer, it helps identify patients with DNA repair defects that may benefit from targeted therapies. In ovarian cancer aids in determining the potential responsiveness to PARP inhibitors, a class of drugs used in DNA repair-deficient tumors. In prostate cancer, it assists in identifying patients who may respond well to certain DNA-damaging agents or PARP inhibitors. Understanding HRD status in pancreatic cancer helps in identifying patients with defects in DNA repair pathways, which may influence treatment decisions. In lung cancer allows for the identification of patients who may benefit from DNA damage response-targeted therapies.

webinar
Dr. Shibichakravarthy Kannan
  • 18th-July-2023, TIME : 5:00PM - 6:00PM
  • 0

HRD (Homologous Recombination Deficiency) evaluation plays a crucial role in assessing the genetic characteristics and treatment strategies for various types of cancers. In breast cancer, it helps identify patients with DNA repair defects that may benefit from targeted therapies. In ovarian cancer aids in determining the potential responsiveness to PARP inhibitors, a class of drugs used in DNA repair-deficient tumors. In prostate cancer, it assists in identifying patients who may respond well to certain DNA-damaging agents or PARP inhibitors. Understanding HRD status in pancreatic cancer helps in identifying patients with defects in DNA repair pathways, which may influence treatment decisions. In lung cancer allows for the identification of patients who may benefit from DNA damage response-targeted therapies.